

# HNE AREA Intensive Care

Approved For: JHH ICU only

## Recombinant Coagulation Factor VII A

**Trade Name:** NovoSeven®

**Presentation:** powder in vials

**Indications:**

1. Haemostasis, prophylaxis (surgery) in patients with inhibitors to coagulation factors VIII or IX.
2. Treatment of life threatening bleeding in patients who:
  - a. Have sufficient Fibrinogen levels
  - b. Have had maximal correction of coagulation abnormalities with blood products.
  - c. Have surgical bleeding causes corrected or in process of correction.
  - d. Are not moribund

Each use of recombinant Factor VIIa in ICU must be approved by the duty Intensivist and the Haematology consultant. More details

**Administration;** Vials with powder in three sizes:

1.2 mg (vial) (use 2.2 mL sterile water to reconstitute)  
2.4 mg (vial) (use 4.3 mL sterile water to reconstitute)  
4.8 mg (vial) (use 8.5 mL sterile water to reconstitute)

Inject the diluent as above into the vial, and gently swirl until dissolved.

Administer the required dose by bolus injection immediately after reconstitution.

**Dose** 90 micrograms per kg of body weight.

**Precautions** Patients who receive rFVIIa should be kept under close observation in case they develop signs and symptoms of untoward activation of the coagulation system or thrombosis.

DIC may be induced in crush injury and sepsis.

May be used in children.

**Compatibilities:**